股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2026年1月31日 狀態: 新提交 FF301 II. 已發行股份及/或庫存股份變動及足夠公眾持股量的確認 致：香港交易及結算所有限公司 公司名稱: 澳至尊國際控股有限公司 呈交日期: 2026年2月2日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 02031 | 說明 | | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 2,000,000,000 | HKD | | 0.01 | HKD | | 20,000,000 | | 增加 / 減少 (-) | | | | | | | HKD | | | | 本月底結存 | | | 2,000,000,000 | HKD | | 0 ...

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年12月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 澳至尊國際控股有限公司 呈交日期: 2026年1月2日 I. 法定/註冊股本變動 FF301 II. 已發行股份及/或庫存股份變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 02031 | 說明 | | | | | | | | | 已發行股份（不包括庫存股份）數目 | | 庫存股份數目 | | 已發行股份總數 | | | 上月底結存 | | | 762,000,000 | | 0 | | 762,000,000 | | 增加 / 減少 (-) | | | | | | | | | 本月底結存 | | | 762,000,000 | | 0 | | 762,000,000 | 第 2 頁 共 10 頁 v 1.1.1 III.已發行股份及/或庫存股 ...

Ausupreme International Holdings Limited 澳至尊國際控股有限公司 (Incorporated in the Cayman Islands with limited liability) N OT IF IC ATI ON LET TE R 通 知 信 函 Dear Non-registered Shareholder(Note 1) , Ausupreme International Holdings Limited (the "Company") – Notice of Publication of 2025/2026 Interim Report (the "Current Corporate Communication(s)") The English and Chinese versions of the Company's Current Corporate Communication (s) are available on the Company's website at www.ausupreme.com and the website of The S ...

Ausupreme International Holdings Limited N OT IF IC ATI ON LET TE R 通 知 信 函 23 December 2025 Dear Registered Shareholder, Ausupreme International Holdings Limited (the "Company") – Notice of Publication of 2025/2026 Interim Report (the "Current Corporate Communication(s)") The English and Chinese versions of the Company's Current Corporate Communication (s) are available on the Company's website at www.ausupreme.com and the website of The Stock Exchange of Hong Kong Limited (the "HKEx's website") at www.hke ...

Financial Performance - Revenue for the six months ended September 30, 2025, was HKD 144,972,000, representing a 14.6% increase from HKD 126,540,000 in the same period of 2024[9] - Gross profit for the same period was HKD 126,817,000, up from HKD 110,347,000, indicating a growth of 15%[9] - The net profit for the period was HKD 17,901,000, which is a 35.5% increase compared to HKD 13,239,000 in the previous year[9] - Basic earnings per share increased to HKD 2.35 from HKD 1.74, reflecting a growth of 35%[9] - Total comprehensive income for the period was HKD 18,461,000, compared to HKD 14,685,000 in the prior year, marking a 25.5% increase[9] - The company reported a pre-tax profit of HKD 21,681,000 for the six months ended September 30, 2025, compared to HKD 15,939,000 for the same period in 2024, representing a growth of 36.5%[14] - Revenue from health supplements increased to HKD 138,589,000, up 15.1% from HKD 120,398,000 in the previous year[19] - Total revenue for the six months reached HKD 144,972,000, a rise of 14.6% compared to HKD 126,540,000 in 2024[19] - The company's profit for the six months ended September 30, 2025, was HKD 17,901,000, compared to HKD 13,239,000 for the same period in 2024, representing a year-on-year increase of approximately 35.5%[35] Cash and Assets - Cash and cash equivalents as of September 30, 2025, were HKD 82,619,000, up from HKD 78,723,000, showing a growth of 4.5%[11] - The company’s cash and cash equivalents at the end of the period were HKD 82,619,000, compared to HKD 80,030,000 at the end of the previous year[14] - Accounts receivable as of September 30, 2025, stood at HKD 27,707,000, compared to HKD 21,064,000 as of March 31, 2025, marking an increase of about 31.7%[36] - As of September 30, 2025, the group's current assets net value was HKD 115,398,000, an increase from HKD 110,807,000 as of March 31, 2025[56] - The company's total liabilities as of September 30, 2025, were HKD 14,979,000, compared to HKD 14,337,000 as of March 31, 2025, indicating a slight increase of about 4.5%[39] Expenses and Costs - The company reported a decrease in financing costs to HKD 494,000 from HKD 562,000, a reduction of 12.1%[9] - Total tax expenses for the six months ended September 30, 2025, amounted to HKD 3,780,000, up from HKD 2,700,000 in 2024, reflecting a growth of about 40%[7] - Depreciation expenses for property, plant, and equipment totaled HKD 8,640,000, an increase from HKD 7,584,000 in the previous year, indicating an increase of approximately 13.9%[30] - Selling and distribution expenses increased by 11.2% to HKD 87,278,000, while general and administrative expenses rose by 15.1% to HKD 18,697,000[52] - The total amount of inventory costs recognized as expenses was HKD 18,155,000, compared to HKD 16,193,000 in 2024, reflecting an increase of approximately 12.1%[30] Inventory and Operations - Inventory increased to HKD 20,913,000 from HKD 19,057,000, reflecting a 9.7% rise[11] - The company continues to focus on the retail and wholesale of health and personal care products, with all revenue derived from this segment[22] - Sales from consignment counters increased by 16.1% to HKD 105,184,000, accounting for 72.5% of total revenue[51] - The company opened one additional specialty store, bringing the total to 19 stores and 68 consignment counters as of September 30, 2025[48] Shareholder Information - The company declared dividends amounting to HKD 15,240,000 during the period[12] - The company has not declared an interim dividend for the six months ended September 30, 2025, consistent with the previous year[31] - The weighted average number of ordinary shares used for calculating basic and diluted earnings per share remained constant at 762,000,000 for both 2025 and 2024[33] - As of September 30, 2025, Beatitudes holds 443,840,000 shares, representing 58.25% of the total issued shares of 762,000,000[69][70] - Gao Yuan holds 93,635,000 shares, accounting for 12.29% of the total issued shares[69][70] Corporate Governance - The audit committee has reviewed and supervised the group's financial reporting system and internal control procedures during the reporting period[82][83] - The company has complied with the corporate governance code requirements, except for the separation of the roles of chairman and CEO[77][79] - The board believes that having the chairman also serve as co-CEO is in the best interest of the group due to his extensive knowledge and network in the industry[79] - The company has maintained a public float of at least 25% of its total issued shares throughout the reporting period[81] Strategic Initiatives - The company plans to continue optimizing its business strategy to adapt to the changing business environment[48] - The group plans to adopt digital and technological transformation to optimize operational processes and enhance efficiency[65] - The strategy includes expanding product diversity to meet the preferences of different customer segments[65] - The group aims to leverage the government's initiatives to attract more visitors to Hong Kong, which is expected to boost the overall retail market[65] Miscellaneous - The company has not granted any stock options since the adoption of the stock option plan on September 12, 2016, and there are no unexercised options as of September 30, 2025[72][73] - The company did not redeem any of its listed securities during the reporting period, nor did it purchase or sell any such securities[74][75] - The group had no significant investments, acquisitions, or disposals in subsidiaries, associates, or joint ventures for the six months ended September 30, 2025[60] - The employee count was 222 as of September 30, 2025, down from 232 a year earlier[62] - The company expresses gratitude to shareholders, business partners, and customers for their continued support[84]

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年11月30日 狀態: 新提交 本月底法定/註冊股本總額： HKD 20,000,000 FF301 第 1 頁 共 10 頁 v 1.1.1 FF301 II. 已發行股份及/或庫存股份變動 致：香港交易及結算所有限公司 公司名稱: 澳至尊國際控股有限公司 呈交日期: 2025年12月1日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 02031 | 說明 | | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 2,000,000,000 | HKD | | 0.01 | HKD | | 20,000,000 | | 增加 / 減少 (-) | | | | | | | HK ...

本文源自：金融界AI电报 澳至尊(02031.HK)发布截至2025年9月30日止六个月中期业绩，收益1.45亿港元，同比增长14.57%;净利 润1790.1万港元，同比增长35.21%;基本每股盈利2.35港仙。 ...

澳至尊(02031)发布截至2025年9月30日止六个月中期业绩，收益1.45亿港元，同比增长14.57%;净利润 1790.1万港元，同比增长35.21%;基本每股盈利2.35港仙。 ...

智通财经APP讯，澳至尊(02031)发布截至2025年9月30日止六个月中期业绩，收益1.45亿港元，同比增 长14.57%;净利润1790.1万港元，同比增长35.21%;基本每股盈利2.35港仙。 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其 準確性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容 而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 Ausupreme International Holdings Limited 澳至尊國際控股有限公司 （於開曼群島註冊成立的有限公司） （股份代號：2031） 截至2025年9月30日止六個月 未經審核中期業績公告 業績 澳至尊國際控股有限公司（「本公司」）之董事（「董事」）會（「董事會」）欣然提呈本公司及其 附屬公司（統稱「本集團」）截至2025年9月30日止六個月（「本期間」）之未經審核簡明綜合 業績，連同有關之比較數字如下： 簡明綜合損益及其他全面收益表 截至2025年9月30日止六個月 | | | 截至9月30日止六個月 | | | --- | --- | --- | --- | | | | 2025年 | 2024年 | | | 附註 | 千港元 | 千港元 | | | | （未經審核） | （未經審核） | | 收益 | 4(a) | 144,972 | 126,540 | | 銷售成本 ...